TABLE 1.

Oligonucleotides used in this work

Name	Sequence (5′ → 3′)a
pri-miR-372 sense	GTTACGGATCCAGATCTCTCAACCTGCGGAGAAGATAC
pri-miR-372 antisense	CAGCCGAATTCTGTAAGGGACCTGTACCCAAGACAG
Cyclin A1 forward	GCGGATCCTTGCCTGAGTGAGC
Cyclin A1 reverse	GCGAATTCGCAGAAGCCTATGA
CDK2 forward	GCGAATTCCCCAGCCCTAATCTCA
CDK2 reverse	GCCTCGAGAACCCTCTTCAGCAATAA
CyclinA1-mut forward	CTGAATGGATGGAGTACCAGAACTTC
CyclinA1-mut reverse	GAAGTTCTGGTACTCCATCCATTCAG
CDK2-mut forward	GTATTAGATGGTCATAAGTTAGCC
CDK2-mut reverse	GGCTAACTTATGACCATCTAATAC
U6-RT	GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACAAAATATGGAAC
miR-372-RT	GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACACGCTC
U6 forward	TGCGGGTGCTCGCTTCGGCAGC
miR-372 forward	GCCCGCAAAGTGCTGCGACAT
Reverse (universal)	CCAGTGCAGGGTCCGAGGT
Actin forward	CGTGACATTAAGGAGAAGCTG
Actin reverse	CTAGAAGCATTTGCGGTGGAC

^a Restriction sites are underlined.